Complete Revascularization vs Culprit Lesion-Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Randomized Clinical Trial.


Journal

JAMA cardiology
ISSN: 2380-6591
Titre abrégé: JAMA Cardiol
Pays: United States
ID NLM: 101676033

Informations de publication

Date de publication:
01 11 2022
Historique:
pubmed: 22 9 2022
medline: 15 11 2022
entrez: 21 9 2022
Statut: ppublish

Résumé

In patients with multivessel coronary artery disease (CAD) presenting with ST-segment elevation myocardial infarction (STEMI), complete revascularization reduces major cardiovascular events compared with culprit lesion-only percutaneous coronary intervention (PCI). Whether complete revascularization also improves angina-related health status is unknown. To determine whether complete revascularization improves angina status in patients with STEMI and multivessel CAD. This secondary analysis of a randomized, multinational, open label trial of patient-reported outcomes took place in 140 primary PCI centers in 31 countries. Patients presenting with STEMI and multivessel CAD were randomized between February 1, 2013, and March 6, 2017. Analysis took place between July 2021 and December 2021. Following PCI of the culprit lesion, patients with STEMI and multivessel CAD were randomized to receive either complete revascularization with additional PCI of angiographically significant nonculprit lesions or to no further revascularization. Seattle Angina Questionnaire Angina Frequency (SAQ-AF) score (range, 0 [daily angina] to 100 [no angina]) and the proportion of angina-free individuals by study end. Of 4041 patients, 2016 were randomized to complete revascularization and 2025 to culprit lesion-only PCI. The mean (SD) age of patients was 62 (10.7) years, and 3225 (80%) were male. The mean (SD) SAQ-AF score increased from 87.1 (17.8) points at baseline to 97.1 (9.7) points at a median follow-up of 3 years in the complete revascularization group (score change, 9.9 [95% CI, 9.0-10.8]; P < .001) compared with an increase of 87.2 (18.4) to 96.3 (10.9) points (score change, 8.9 [95% CI, 8.0-9.8]; P < .001) in the culprit lesion-only group (between-group difference, 0.97 points [95% CI, 0.27-1.67]; P = .006). Overall, 1457 patients (87.5%) were free of angina (SAQ-AF score, 100) in the complete revascularization group compared with 1376 patients (84.3%) in the culprit lesion-only group (absolute difference, 3.2% [95% CI, 0.7%-5.7%]; P = .01). This benefit was observed mainly in patients with nonculprit lesion stenosis severity of 80% or more (absolute difference, 4.7%; interaction P = .02). In patients with STEMI and multivessel CAD, complete revascularization resulted in a slightly greater proportion of patients being angina-free compared with a culprit lesion-only strategy. This modest incremental improvement in health status is in addition to the established benefit of complete revascularization in reducing cardiovascular events.

Identifiants

pubmed: 36129696
pii: 2796743
doi: 10.1001/jamacardio.2022.3032
pmc: PMC9494273
doi:

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1091-1099

Subventions

Organisme : British Heart Foundation
ID : CH/09/002/26360
Pays : United Kingdom
Organisme : CIHR
Pays : Canada

Investigateurs

John Amerena (J)
Ahmad Farshid (A)
Chris Zeitz (C)
Stephen Duffy (S)
Dion Stub (D)
Melanie Freeman (M)
Irene Lang (I)
Suzanne Pourbaix (S)
Antoine Guedes (A)
Adrian Kormann (A)
Paulo Caramori (P)
José Carlos Nicolau (JC)
Márcio Santos (M)
José Antonio Marin-Neto (JA)
José Francisco Kerr Saraiva (JF)
Jose de Ribamar Costa (JR)
Robert Welsh (R)
Kapil Bhagirath (K)
Saleem A Kassam (SA)
Anthony Della Siega (A)
Vladimír Džavík (V)
Robert Boone (R)
Asim Cheema (A)
Mouhieddin Traboulsi (M)
Robert Teskey (R)
Tycho Vuurmans (T)
John Ducas (J)
Eric Cohen (E)
Michel Nguyen (M)
Philippe Généreux (P)
Erick Schampaert (E)
Hahn Hoe Kim (HH)
Najaf Nadeem (N)
André Kokis (A)
Warren Ball (W)
Payam Dehghani (P)
Brian Wong (B)
Bruce Sussex (B)
Samer Mansour (S)
Kushal Dighe (K)
Jean-Philippe Pelletier (JP)
Yuan Wu (Y)
Xiao-Shu Cheng (XS)
Qingsheng Wang (Q)
Jia Shaobin (J)
Ma Yitong (M)
Yin Yuehui (Y)
Wei Wu (W)
Qun Zheng (Q)
Qiang Fu (Q)
Boris Vesga (B)
Ota Hlinomaz (O)
Kari Niemelä (K)
Olivier Varenne (O)
Laurent Feldman (L)
Olivier Dubreuil (O)
Jean Guillaume Dillinger (JG)
Emile Ferrari (E)
Olivier Nallet (O)
Oliver Bruder (O)
Georgios Hahalis (G)
Antonios Ziakas (A)
Vassilis Voudris (V)
Zsolt Kőszegi (Z)
Ivan Horvath (I)
Shmuel Fuchs (S)
Michael Kapeliovich (M)
Fabrizio D'Ascenzo (F)
Giuseppe Di Pasquale (G)
Vincenzo Guiducci (V)
Gianluca Campo (G)
Ferdinando Varbella (F)
Darar Al Khdair (D)
Vytautas Abraitis (V)
Sasko Kedev (S)
Juan Carlos Perez Alva (JC)
Bogdan Janus (B)
Artur Baszko (A)
Hélder Pereira (H)
Fausto Pinto (F)
Maria Dorobantu (M)
Khalid Alhabib (K)
Mohammad Al Shehri (M)
Mpiko Ntsekhe (M)
Pravin Manga (P)
José Ramón González Juanatey (JRG)
Pablo Avanzas (P)
Francisco Fernández Aviles (F)
Andrés Iñiguez (A)
Antonio Fernandez Ortiz (A)
Fina Mauri (F)
Iñigo Lozano (I)
Ignacio Sánchez Pérez (I)
Giovanna Sarno (G)
Robert Kastberg (R)
Florim Cuculi (F)
Habib Haouala (H)
Richard Oliver (R)
Alisdair Ryding (A)
Andrew Sutton (A)
David Newby (D)
Benjamin Wrigley (B)
Sam Firoozi (S)
Joanne Shannon (J)
Michael Seddon (M)
Neville Kukreja (N)
Konrad Grosser (K)
Joseph Mills (J)
Ian Webb (I)
Tim Wells (T)
Robin van Lingen (R)
Michael Ragosta (M)
Peter Johnston (P)
Sean Wilson (S)
Stacey Clegg (S)
Richard Bach (R)
Donald Cutlip (D)
Jason Call (J)
John Lopez (J)
Catalin Toma (C)
Kevin Marzo (K)
Paul Frey (P)
Mark Menegus (M)
Nabil Dib (N)
Chao-Wei Hwang (CW)
Steven Laster (S)
Ryan Reeves (R)
Mamoo Nakamura (M)
Salman Arain (S)
Thomas Stuckey (T)
Dhananjai Menzies (D)

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Shamir R Mehta (SR)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Jia Wang (J)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

David A Wood (DA)

University of British Columbia, Vancouver, British Columbia, Canada.

John A Spertus (JA)

Saint Luke's Mid America Heart Institute and the University of Missouri-Kansas City, Kansas City.

David J Cohen (DJ)

Cardiovascular Research Foundation, New York, New York.
St Francis Hospital, Roslyn, New York.

Roxana Mehran (R)

The Zena A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

Robert F Storey (RF)

Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.

Philippe Gabriel Steg (PG)

Université Paris Cité, INSERM U-1148, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France and FACT (French Alliance for Cardiovascular Trials), Paris, France.

Natalia Pinilla-Echeverri (N)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Tej Sheth (T)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Kevin R Bainey (KR)

University of Alberta, Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada.

Sripal Bangalore (S)

New York University Grossman School of Medicine, New York.

Warren J Cantor (WJ)

Southlake Regional Health Centre, University of Toronto, Toronto, Ontario, Canada.

David P Faxon (DP)

Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Laurent J Feldman (LJ)

Université Paris Cité, INSERM U-1148, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France and FACT (French Alliance for Cardiovascular Trials), Paris, France.

Sanjit S Jolly (SS)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

Vijay Kunadian (V)

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University and Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

Shahar Lavi (S)

Western University, London Health Sciences Centre, London, Ontario, Canada.

Jose Lopez-Sendon (J)

Hospital Universitario La Paz, UAM, IdiPaz Research Institute, Madrid, Spain.

Mina Madan (M)

Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Raul Moreno (R)

Hospital Universitario La Paz, UAM, IdiPaz Research Institute, Madrid, Spain.

Sunil V Rao (SV)

NYU Langone Health System, New York.

Josep Rodés-Cabau (J)

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec City, Quebec, Canada.

Goran Stankovic (G)

Serbia to Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Shrikant I Bangdiwala (SI)

Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

John A Cairns (JA)

University of British Columbia, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH